Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3,' said Martin Lange, executive vice president for Development at Novo Nordisk. 'We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the phase 3 programme.'
Novo Nordisk is now planning to initiate a phase 3 development programme with amycretin for adults with overweight or obesity during the first quarter of 2026.
About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration.
Oral Amycretin Phase 1 trial - The trial evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.Subcutaneous Amycretin Phase 1b/2a trial - The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks.
About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media:
Ambre James-Brown +45 3079 9289abmo@novonordisk.com
Liz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com
Sina Meyer +45 3079 6656azey@novonordisk.com
Max Ung+45 3077 6414 mxun@novonordisk.com
Frederik Taylor Pitter +1 609 613 0568fptr@novonordisk.com
Company announcement No 17 / 2025
Attachment
CA250612-amycretin-to-phase-3-clean
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S' (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72, 36.8% of people treated with Wegovy achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% treated with placebo. 62.9% of people treated with Wegovy achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% treated with part 2, the objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks. Part 2 of the ESSENCE trial will continue with the expected readout in 2029. The approval marks a positive development for Novo Nordisk as the European company faces downward sales for its GLP-1 products due to slower-than-expected penetration of its branded GLP-1 treatments and persistent use of compounded GLP-1 alternatives. Novo Nordisk projects 2025 sales growth to be in the range of 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%. In May, Health Canada accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly therapy for MASH. In March 2024, the FDA approved a label expansion for Wegovy based on a supplemental New Drug Application for reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD). The approval was based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care. The findings from SELECT also showed that risk reductions in MACE were achieved in up to five years. In addition, the label was updated to include data from SELECT showing a risk reduction in cardiovascular death by 15% and a risk reduction of death from any cause by 19%, compared to placebo. In March 2024, Madrigal Pharmaceuticals Inc.'s (NASDAQ:MDGL) Rezdiffra (resmetirom) became the first FDA-approved treatment for patients with liver scarring due to fatty liver disease. The FDA granted accelerated approval, and continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials. Price Action: NVO shares climbed 7.14% to $56.15, up $3.74, in after-hours trading on Friday. Read Next:Photo by Tobias Arhelger via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NOVO NORDISK (NVO): Free Stock Analysis Report This article Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
33 minutes ago
- Yahoo
Why Novo Nordisk Stock Popped Monday
Key Points Novo Nordisk is cutting Ozempic prices again. It's also partnering with GoodRx to cut prices on Ozempic and Wegovy. And Novo Nordisk just won approval to use Wegovy to treat liver disease. 10 stocks we like better than Novo Nordisk › Shares of Novo Nordisk (NYSE: NVO), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products. Two of these announcements concern weight loss. One doesn't. Novo Nordisk cuts prices In a pair of press releases this morning, Novo announced it's cutting the cash cost for 0.5 mg, 1 mg, and 2 mg doses of Ozempic to $499 per month "for self-paying patients." And separately, the company says it's collaborating with GoodRx to sell all dose sizes of both Ozempic and Wegovy to patients for the $499 price. In both instances, Novo appears to be targeting competition from telehealth providers like Ro and Hims & Hers Health, declaring, "We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives [because of price], that's one too many." On top of all that, CNBC reports that Novo's Wegovy GLP-1 drug has won FDA approval for treatment of metabolic dysfunction-associated steatohepatitis (MASH) liver disease in adults. Is Novo Nordisk stock a buy? In a statement, Novo pointed out that Wegovy is now "the first and only GLP-1 treatment approved for MASH," a disease that affects about 5% of U.S. adults, opening up a new market that (for now) neither Hims & Hers nor archrival Eli Lilly can compete in. Valued at just 13 times trailing earnings, Novo Nordisk stock was already looking cheap based on its 3.5% dividend yield and 11.3% projected long-term earnings growth rate. While it's too soon to say how much the MASH indication will add to that growth rate, it will add something. That fact alone makes Novo Nordisk stock even more of a buy today. Do the experts think Novo Nordisk is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Novo Nordisk make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,070% vs. just 184% for the S&P — that is beating the market by 885.55%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Popped Monday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
36 minutes ago
- Bloomberg
Novo Cuts Price of Ozempic in Half for Cash Buyers
Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients to $499 a month through NovoCare and partnering with GoodRx Holdings Inc. to offer it at the same price at US pharmacies. Bloomberg's Madison Muller reports. (Source: Bloomberg)
